Chalotte, NC -- July 20, 2018 -- InvestorsHub NewsWire -- Level
Brands, Inc. (NYSE
American: LEVB), an innovative marketing and licensing company
that provides bold, unconventional, and socially responsible
branding for leading businesses, today announced a seven-year
licensing agreement with Boston Therapeutics, Inc. (OTCQB:
BTHE), an innovator in the design, development and
commercialization of novel therapeutics for diabetes and related
complications. Under the terms of the agreement, Boston
Therapeutics is licensing the kathy Ireland® Health &
Wellness brand to market its popular diabetes
supplement, Sugardown®. Deal generates $850,000 in upfront
marketing fees plus ongoing royalties.
“CDC Research shows that diagnosis of diabetes and prediabetes
is on the rise”
Boston Therapeutics will pay Level Brands an initial marketing
fee of $850,000 to produce intellectual property to support the
marketing efforts of the newest product to be branded
under kathy ireland® Health & Wellness, plus
ongoing royalties.
Diabetes affects an estimated 371 million people worldwide,
according to the International Diabetes Federation., and is growing
at a rate that requires immediate intervention. In the U.S., more
than 100 million adults are now living with diabetes or
prediabetes, according to a report released by the Centers for
Disease Control (CDC) in July 2017.
Sugardown®, a chewable dietary supplement for glycemic
health, has been shown in clinical studies to help reduce
post-meal elevation of blood sugar levels by up to 60% using
galactomannans, a group of complex polysaccharides derived from
plants that have been shown to possess significant activity in
moderating post-meal blood glucose levels. Managing blood sugar
levels is one key to maintaining optimum health and body weight,
especially for those at risk of diabetes or pre-diabetes.
“CDC Research shows that diagnosis of diabetes and prediabetes
is on the rise,” says Kathy Ireland®, Level Brands’
Chairman Emeritus and Chief Brand Strategist. “Diabetes is a
contributing factor to other serious health conditions such as
obesity, heart disease and kidney disease. For this reason, we are
thrilled to partner with Boston Therapeutics, whose scientific
research and development of this innovative supplement reflects the
dedication of the kathy Ireland® Health &
Wellness brand to bring the most evolved wellness options
to market.” Ms. Ireland is one of the top ten women's health
advocates in America, according to UCLA.
Carl W. Rausch, CEO of Boston Therapeutics (OTCQB:
BTHE), stated, “We are pleased to work with the kathy
Ireland® Health & Wellness brand both domestically
and internationally to introduce what will hopefully be only the
first of many innovative, clinically-tested agents. Implementing
this strategy represents the next phase in our commercialization of
sugardown® technology, a product we
believe can play a positive role in the lives of many individuals
who must watch their blood sugar and are at risk for complications
from metabolic diseases, most well-known of which is diabetes. Our
partnership with Level Brands gives us the leverage and educational
exposure we need to maximize the number of customers we reach with
our product messaging.”
Sugardown® is the first of many opportunities for Boston
Therapeutics to leverage the kathy Ireland® Health &
Wellness brand and the worldwide presence that Ms.
Ireland brings. Future products under branding consideration
include other innovative and disruptive products in the area of
regenerative therapeutics and oxygen perfusion as it relates to
ischemia, peripheral circulation, improved transplant outcomes, and
worldwide blood product supplies.
Boston Therapeutics will pay Level Brands an initial marketing
fee of $850,000, paid pursuant to a $450,000 promissory note and
$400,000 of Boston Therapeutics’ common stock. Level Brands will
also earn royalties on gross sales using the licensed mark of 5% of
the first $10 million in sales; 7.5% of sales between $10 million
and $50 million; and 10% on sales exceeding $50 million.
About Level Brands, Inc. (www.LevelBrands.com)
Level Brands creates bold, unconventional, and socially
responsible branding for leading businesses. Level Brands
specializes in corporate brand management and consumer products
marketing art, beauty, fashion, health and wellness, and
entertainment. Licensed brand marketing is at the core of the Level
Brands businesses, among which are Ireland Men One or I’M1, for
millennial men and the women who love them; Encore Endeavor One or
EE1, corporate brand management and producer of experiential
entertainment events and products across multiple
platforms; kathy ireland® Health & Wellness; and
Beauty & Pin-Ups, Level Brands’ hair-care and disruptive
women’s-products brand.
Forward-Looking Statements
This press release contains certain forward-looking statements
that are based upon current expectations and involve certain risks
and uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties, and other factors, some of
which are beyond our control and difficult to predict and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including, without
limitation, statements made with respect to our material dependence
on our relationship with kathy ireland® Worldwide, our limited
operating history, our ability to expand our business and
significantly increase our revenues and our ability to report
profitable operations in future periods, among others. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading "Risk Factors" in Level Brands, Inc.'s Annual Report on
Form 10-K for the fiscal year ended September 30, 2017 as filed
with the Securities and Exchange Commission (the "SEC") on December
26, 2017 and our other filings with the SEC. All forward-looking
statements involve significant risks and uncertainties that could
cause actual results to differ materially from those in the
forward-looking statements, many of which are generally outside the
control of Inuvo and are difficult to predict. Level Brands, Inc.
does not undertake any duty to update any forward-looking
statements except as may be required by law.
Contacts
RedChip Companies
Paul Kuntz, 407-644-4256, ext. 105
paul@redchip.com